XOMA (NASDAQ:XOMA) Shares Cross Above 200 Day Moving Average of $23.29

Shares of XOMA Co. (NASDAQ:XOMA) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $23.29 and traded as high as $25.09. XOMA shares last traded at $24.64, with a volume of 7,496 shares changing hands.

Analyst Upgrades and Downgrades

XOMA has been the topic of a number of analyst reports. Leerink Partnrs reaffirmed an “outperform” rating on shares of XOMA in a research report on Monday, April 29th. SVB Leerink started coverage on shares of XOMA in a report on Monday, April 29th. They issued an “outperform” rating and a $40.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $74.00 price objective on shares of XOMA in a report on Friday, May 31st.

XOMA Stock Performance

The company has a current ratio of 9.45, a quick ratio of 9.45 and a debt-to-equity ratio of 1.39. The stock has a 50 day moving average price of $24.81 and a two-hundred day moving average price of $23.31.

XOMA (NASDAQ:XOMA) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.15). The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $0.96 million. XOMA had a negative return on equity of 26.00% and a negative net margin of 705.23%. Sell-side analysts predict that XOMA Co. will post -1.76 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in XOMA stock. BNP Paribas Financial Markets raised its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 55.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,543 shares of the biotechnology company’s stock after acquiring an additional 1,266 shares during the period. BNP Paribas Financial Markets’ holdings in XOMA were worth $85,000 at the end of the most recent quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.